Endometriosis Pipeline

DelveInsight’s, “Endometriosis Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Endometriosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Endometriosis Understanding

Endometriosis Overview

Endometriosis is defined as the presence of endometrial glands and stroma like lesions outside of the uterus. The lesions can be peritoneal lesions, superficial implants or cysts on the ovary, or deep infiltrating disease. While there is no definitive etiology of endometriosis, there are several hypotheses regarding how endometriotic lesions develop. One possible mechanism is retrograde menstruation, a feature of the menstrual cycle in women and non-human primates, which is an outflow of the endometrial lining through the patent fallopian tubes into the pelvic space. This retrograde flow, along with potential hematogenous or lymphatic circulation, may result in the seeding of endometrial tissue in ectopic sites.

Symptoms of endometriosis include: gradually increasing acute premenstrual pain, pelvic pain, pain in the sacral region of the spine, dysmenorrhea, painful ovulation, pain during intercourse, pain when defecating, pain when urinating, pain radiating to the back, abundant irregular menstruation, blood in the stool, diarrhea or constipation, infertility and chronic fatigue.

The understanding of the pathophysiology of endometriosis remains incomplete in many aspects, and there is not a coherent suggested theory to explain all different types of endometriosis, integrating the epigenetic, genetic, immunological, and environmental data. Of the proposed pathogenic theories, the most plausible is Sampson’s theory, suggesting that with retrograde menstruation, viable cells, and menstrual fragments can migrate through the Fallopian tubes, infiltrate into the peritoneal cavity, and then proliferate and cause chronic inflammation. The fact that retrograde menstruation is a phenomenon caused in a large proportion of women of reproductive age, but not all of them suffer from endometriosis, indicates that retrograde menstruation is not enough by itself to cause endometriosis, indicates that there are also other factors contributing to the generation of disease. Other theories, such as the coelomic metaplastic theory and the vascular and lymphatic metastatic theory, are necessary to explain some forms of endometriosis. The role of oxidative stress and ROS, together with genetic, epigenetic, and environmental factors, must be integrated for a more complete picture of the pathogenesis of endometriosis.

Diagnosis typically begins with a detailed medical history and gynecological examination, where findings such as pelvic pain, adnexal masses, uterine immobility, vaginal tenderness, or palpable nodules may raise suspicion. However, the absence of physical findings does not exclude the disease. Laparoscopy with histological biopsy remains the gold standard for diagnosis, although it is invasive and associated with surgical risks. Consequently, non-invasive diagnostic approaches such as transvaginal ultrasound and magnetic resonance imaging are increasingly utilized, particularly for detecting ovarian endometriomas and deep infiltrating lesions. Biomarkers such as CA125 and certain miRNAs have also been investigated, but none currently provide sufficient diagnostic specificity or reliability as standalone tests.

Treatment of endometriosis is primarily aimed at symptom relief and fertility improvement rather than cure, as the disease is chronic and recurrent. Management options are broadly divided into pharmacological and surgical approaches. First-line medical therapies include non-steroidal anti-inflammatory drugs (NSAIDs), combined hormonal contraceptives, and progestins, which help reduce pain and suppress endometrial lesion growth through hormonal regulation. Second-line therapies include gonadotropin-releasing hormone (GnRH) analogs and danazol, which suppress estrogen production but may cause significant hypoestrogenic or androgenic side effects. Empirical medical treatment may be initiated even without histological confirmation in symptomatic women. Surgical intervention, particularly laparoscopic excision or ablation of endometriotic lesions and adhesions, is considered for patients with persistent symptoms, infertility, or contraindications to medical therapy.

"Endometriosis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endometriosis pipeline landscape is provided which includes the disease overview and Endometriosis treatment guidelines. The assessment part of the report embraces, in depth Endometriosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endometriosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest insights into the Endometriosis pipeline, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Endometriosis Pipeline Report Highlights

The Endometriosis companies and academics are working to assess challenges and seek opportunities that could influence Endometriosis R&D. The therapies under development are focused on novel approaches to treat/improve Endometriosis.

Endometriosis Emerging Drugs Analysis

This segment of the Endometriosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Endometriosis Emerging Drugs

HMI-115: Hope Medicine (Nanjing) Co., Ltd

HMI-115 is a first-in-class monoclonal antibody drug targeting the prolactin receptor (PRLR), that Hope Medicine owns the global rights. The product candidate is being developed for multiple indications globally. Potential indications for the antibody include Endometriosis (EM), Androgenic Alopecia (AGA), and other chronic diseases. This antibody has shown excellent characteristics in animal models including non-human primate (NHP) models and human safety. Currently the drug is in Phase III stage of its development for the treatment of Endometriosis.

Merigolix: TiumBio

Merigolix (TU2670) is an oral GnRH antagonist that can bind to pituitary receptors to suppress estradiol hormone. The existing treatment GnRH agonists, lowers patient comfort levels as it’s in an injection form and inhibits sex hormones to the level of menopause, resulting in serious side effects such as bone loss. TU2670 is an oral GnRH antagonist that only suppresses hormone levels to the level of efficacy, improving both side effects and ease of administration by oral. In addition, being a sex hormone control mechanism, it allows for indication expansion to precocious puberty, test-tube baby, infertility treatment, etc. The drug is currently being evaluated under Phase II clinical trial for the treatment of endometriosis.

Nibrozetone (RRx-001): EpicentRx

Nibrozetone, also known as RRx-001, has a unique mechanism of action that involves both anti-inflammatory and antioxidant properties. It has a dual mechanism of action, fragmenting to release metabolites such as nitric oxide (NO) and other nitrogen-centered free radicals in hypoxic environments, targeting diseases like cancer. In non-hypoxic environments, RRx-001 has anti-toxicity activity through direct inhibition of the NLRP3 inflammasome and upregulation of the master antioxidant transcription factor, Nrf2. Additionally, it inhibits the CD47 antigen, involved in immune cell function and tumor progression. Currently, the drug is in the Phase I stage of its development for the treatment of endometriosis.

Further product details are provided in the report……..

Endometriosis Drug Therapeutic Assessment

This segment of the report provides insights about the different Endometriosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Endometriosis Players in Endometriosis

There are approx. 20+ key companies which are developing the therapies for Endometriosis. The companies which have their Endometriosis drug candidates in the most advanced stage, i.e. Phase III include, Hope Medicine (Nanjing) Co., Ltd.

Endometriosis Clinical Trial Phases

DelveInsight’s report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Endometriosis Drug Route of Administration

Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Endometriosis Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Endometriosis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Endometriosis Clinical Trial Activities

The Endometriosis pipeline report provides insights into different Endometriosis clinical trials within phase II, I, preclinical and discovery stage. It also analyses Endometriosis therapeutic drugs key players involved in developing key drugs.

Endometriosis Pipeline Development Activities

The Endometriosis clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endometriosis drugs.

Endometriosis Pipeline Report Insights

• Endometriosis Pipeline Analysis
• Endometriosis Therapeutic Assessment
• Endometriosis Unmet Needs
• Impact of Endometriosis Drugs

Endometriosis Pipeline Report Assessment

• Endometriosis Pipeline Product Profiles
• Endometriosis Therapeutic Assessment
• Endometriosis Pipeline Assessment
• Endometriosis Inactive drugs assessment
• Endometriosis Market Unmet Needs

Discover actionable insights into the Endometriosis market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered In The Endometriosis Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Endometriosis drugs?
• How many Endometriosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Endometriosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Endometriosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Endometriosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Endometriosis Key Players

• Hope Medicine (Nanjing) Co., Ltd
• TiumBio
• EpicentRx
• Ferring Pharmaceuticals
• Gesynta Pharma
• VaRi Bioscience
• Viramal
• Tanabe Pharma Corporation
• Gynica
• Absci Corp.

Endometriosis Key Products

• HMI-115
• Merigolix
• Nibrozetone (RRx-001)
• Quinagolide
• Vipoglanstat
• VR103
• VML 0501
• MT-2990
• IntraVagS301
• ABS-201

Explore comprehensive insights into Endometriosis epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.